− GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Now Available by Prescription for Intravenous or Subcutaneous Use in People Aged ...

Neurologist Susan W. Lee, DO, answers common questions about this treatment option for myasthenia gravis. Intravenous immunoglobulin (IVIG) is a pooled collection of antibodies derived from donors’ ...

Discover tips for managing swelling, redness, and pain at subcutaneous immunoglobulin (SCIg) infusion sites for primary ...

For people living with primary immunodeficiency (PI), immunoglobulin replacement therapy (Ig) is a cornerstone of treatment. It helps prevent serious infections, reduces hospitalizations, and supports ...

SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...

In a recent study posted to the medRxiv* preprint server, researchers comparatively evaluated antibody (Ab) responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among ...

Findings showed after 52 weeks, significant improvements in 2MWD and 6MWD were seen with Flebogamma 5% DIF 1mg/kg compared with placebo. Topline data were announced from a phase 2/3 trial evaluating ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Did you know that a component of your blood could be used ...

When you live with a chronic condition, you know it’s necessary to work with your healthcare provider to develop a treatment plan. The post Managing Chronic Conditions At Home with IVIG Infusions ...

ARLINGTON, Texas, December 02, 2025--(BUSINESS WIRE)--AOM Infusion ("AOM"), a leading provider of specialty infusion and pharmacy services for chronic and complex conditions, has been selected by ...

“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...